AMPLATZER PFO Occluder Post Approval Study

NCT ID: NCT03309332

Last Updated: 2025-11-13

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

ACTIVE_NOT_RECRUITING

Clinical Phase

NA

Total Enrollment

1214 participants

Study Classification

INTERVENTIONAL

Study Start Date

2018-01-31

Study Completion Date

2030-02-05

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this single arm, multi-center study is to confirm the safety and effectiveness of the AMPLATZER™ PFO Occluder in the post Approval Setting.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

A maximum of 1214 adult subjects will be enrolled at up to 100 centers in the U.S. and Canada. Subjects will have follow-up at 1 month, 6 months, 12 months and annually thereafter through 5 years post implant.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Stroke Patent Foramen Ovale

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

PREVENTION

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Device

Subjects implanted with the AMPLATZER™ PFO Occluder.

Group Type EXPERIMENTAL

AMPLATZER™ PFO Occluder

Intervention Type DEVICE

Implantation of the AMPLATZER™ PFO Occluder in the PFO

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

AMPLATZER™ PFO Occluder

Implantation of the AMPLATZER™ PFO Occluder in the PFO

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

• Subjects with a PFO who have had an ischemic stroke within the last 547 days

Exclusion Criteria

* Atherosclerosis or other arteriopathy of the intracranial and extracranial vessels associated with a ≥ 50% lumen diameter supplying the involved lesion
* Intra-cardiac thrombus or tumor
* Documented evidence of venous thrombus in the vessels through which access to the PFO is gained
* Acute or recent (within 6 months prior to consent) myocardial infarction or unstable angina
* Left ventricular aneurysm or akinesis
* Mitral valve stenosis or severe mitral regurgitation requiring intervention irrespective of etiology
* Aortic valve stenosis (mean gradient \>40 mmHg) or severe aortic valve regurgitation
* Mitral or aortic valve vegetation or prosthesis
* Aortic arch plaques protruding greater than 4mm into the aortic lumen
* Left ventricular dilated cardiomyopathy with depressed left ventricular ejection fraction (LVEF less than 35%)
* Subjects with other source of right to left shunts, including an atrial septal defect and/or fenestrated septum
* Chronic, persistent, or paroxysmal atrial fibrillation or atrial flutter
* Pregnancy at the time of implant
* Age less than 18 years or greater than 60 years at time of consent
* Active endocarditis or other untreated infections
* Organ failure (kidney, liver or lung). Kidney failure: Poor urine output of less than 1 cc/kg/hr with elevated BUN levels (above the normal reference range for the laboratory at the investigational site). Liver failure: Liver enzymes outside the normal reference range for the laboratory at the investigational site: poor liver function as assessed by elevated PT (above the normal reference range for the laboratory at the investigational site) and low total protein and albumin (below the normal reference range for the laboratory at the investigational site). Lung failure: Respiratory failure is retention of carbon dioxide more than 60 mmHg, poor oxygenation with oxygen tension less than 40 mmHg in room air or the need for assisted ventilation.
* Uncontrolled hypertension defined as sustained elevated systemic blood pressure to more than 160/90 mmHg with medications
* Uncontrolled diabetes defined as continued elevated glucose levels in spite of administration of insulin/levels of more than 200 mg with presence of glucose in the urine
* Diagnosis of lacunar infarct probably due to intrinsic small vessel as qualifying stroke event Definition: Ischemic stroke in the distribution of a single, small deep penetrating vessel in a patient with any of the following: 1) a history of hypertension (except in the first week post stroke); 2) history of diabetes mellitus; 3) Age \>/= 50; or 4) MRI or CT shows leukoaraiosis greater than symmetric, well-defined periventricular caps or bands (European Task Force on Age-Related White Matter Changes rating scale score \> 0)
* Arterial dissection as cause of stroke
* Subjects who test positive with one of the following hypercoagulable states; Anticardiolipin Ab of the IgG or IgM (≥30), Lupus anticoagulant, B2-glycoprotein-1 antibodies (≥30) or persistently elevated homocysteine (\>20)
* Unable to take antiplatelet therapy
* Anatomy in which the AMPLATZERTM PFO Occluder device size required would interfere with intracardiac or intravascular structures such as valves or pulmonary veins
* Vasculature, through which access to the PFO is gained, is inadequate to accommodate the appropriate sheath size
* Malignancy or other illness where life expectancy is less than 2 years
* Subjects who will not be available for follow-up for the duration of the trial
* Inability to obtain Informed Consent from patient
* Index stroke of poor outcome (modified Rankin score greater than 3)
Minimum Eligible Age

18 Years

Maximum Eligible Age

60 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Abbott Medical Devices

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Barathi Sethuraman, PhD

Role: STUDY_DIRECTOR

Abbott

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

University of Alabama at Birmingham

Birmingham, Alabama, United States

Site Status

Heart Center Research, LLC

Huntsville, Alabama, United States

Site Status

Chandler Regional Medical Center

Chandler, Arizona, United States

Site Status

St. Joseph's Hospital and Medical Center

Phoenix, Arizona, United States

Site Status

Scottsdale Healthcare Shea

Scottsdale, Arizona, United States

Site Status

Pima Heart Physicians, PC

Tucson, Arizona, United States

Site Status

UAMS Medical Center

Little Rock, Arkansas, United States

Site Status

Kaiser Permanente Los Angeles Medical Center

Los Angeles, California, United States

Site Status

USC University Hospital

Los Angeles, California, United States

Site Status

Ronald Reagan UCLA Medical Center

Los Angeles, California, United States

Site Status

Sutter Medical Center

Sacramento, California, United States

Site Status

San Diego Cardiac Center

San Diego, California, United States

Site Status

University of California at San Francisco

San Francisco, California, United States

Site Status

Stanford University Medical Center

Stanford, California, United States

Site Status

Los Robles Hospital and Medical Center

Thousand Oaks, California, United States

Site Status

University of Colorado Hospital

Aurora, Colorado, United States

Site Status

Memorial Hospital of Colorado Springs

Colorado Springs, Colorado, United States

Site Status

Denver Heart

Denver, Colorado, United States

Site Status

South Denver Cardiology Associates PC

Littleton, Colorado, United States

Site Status

MedStar Washington Hospital Center

Washington D.C., District of Columbia, United States

Site Status

St. Vincent's Medical Center

Jacksonville, Florida, United States

Site Status

Baptist Medical Center

Jacksonville, Florida, United States

Site Status

First Coast Cardiovascular Institute

Jacksonville, Florida, United States

Site Status

Orlando Health

Orlando, Florida, United States

Site Status

Cleveland Clinic Florida

Weston, Florida, United States

Site Status

Augusta University

Augusta, Georgia, United States

Site Status

Northeast Georgia Medical Center

Gainesville, Georgia, United States

Site Status

WellStar Kennestone Hospital

Marietta, Georgia, United States

Site Status

Rush University Medical Center

Chicago, Illinois, United States

Site Status

Prairie Education and Research Cooperative

Springfield, Illinois, United States

Site Status

HCA Midwest Division, Menorah Medical Center

Overland Park, Kansas, United States

Site Status

University of Kentucky

Lexington, Kentucky, United States

Site Status

Baptist Hospital East

Louisville, Kentucky, United States

Site Status

Ochsner Medical Center

New Orleans, Louisiana, United States

Site Status

Johns Hopkins University Hospital

Baltimore, Maryland, United States

Site Status

Tufts Medical Center

Boston, Massachusetts, United States

Site Status

Charlton Memorial Hospital

Fall River, Massachusetts, United States

Site Status

McLaren Health Care Corporation

Auburn Hills, Michigan, United States

Site Status

Henry Ford Hospital

Detroit, Michigan, United States

Site Status

Children's Hospital of Michigan

Detroit, Michigan, United States

Site Status

Sparrow Clinical Research Institute

Lansing, Michigan, United States

Site Status

St. Mary's Hospital

Duluth, Minnesota, United States

Site Status

Minneapolis Heart Institute

Minneapolis, Minnesota, United States

Site Status

St. Cloud Hospital

Saint Cloud, Minnesota, United States

Site Status

Washington University School of Medicine

St Louis, Missouri, United States

Site Status

Mercy Hospital South

St Louis, Missouri, United States

Site Status

Providence St. Patrick Hospital

Missoula, Montana, United States

Site Status

University of Nebraska Medical Center

Omaha, Nebraska, United States

Site Status

Newark Beth Israel Medical Center

Newark, New Jersey, United States

Site Status

Mount Sinai Hospital

New York, New York, United States

Site Status

New York Presbyterian Hospital/ Cornell University

New York, New York, United States

Site Status

Stony Brook University Medical Center

Stony Brook, New York, United States

Site Status

Novant Health Heart and Vascular Research

Charlotte, North Carolina, United States

Site Status

Moses H Cone Memorial Hospital

Greensboro, North Carolina, United States

Site Status

Forsyth Medical Center

Winston-Salem, North Carolina, United States

Site Status

Jewish Hospital

Cincinnati, Ohio, United States

Site Status

TriHealth Bethesda North Hospital

Cincinnati, Ohio, United States

Site Status

Ohio Health Research Institute

Columbus, Ohio, United States

Site Status

Ohio State University

Columbus, Ohio, United States

Site Status

Mt Carmel East

Columbus, Ohio, United States

Site Status

Kaiser Sunnyside Medical Center

Clackamas, Oregon, United States

Site Status

Providence Heart and Vascular Institute

Portland, Oregon, United States

Site Status

Geisinger Medical Center

Danville, Pennsylvania, United States

Site Status

Penn State Milton S Hershey Medical Center

Hershey, Pennsylvania, United States

Site Status

Allegheny General Hospital - ASRI

Pittsburgh, Pennsylvania, United States

Site Status

Lexington Medical Center

West Columbia, South Carolina, United States

Site Status

Sanford USD Medical Center

Sioux Falls, South Dakota, United States

Site Status

Erlanger Medical Center

Chattanooga, Tennessee, United States

Site Status

Tennova Healthcare - Turkey Creek Medical Center

Knoxville, Tennessee, United States

Site Status

Ascension Texas Cardiovascular Research

Austin, Texas, United States

Site Status

HCA Houston Healthcare Medical Center

Houston, Texas, United States

Site Status

University of Texas Health Science Center at Houston

Houston, Texas, United States

Site Status

Baylor Scott & White - The Heart Hospital Baylor Plano

Plano, Texas, United States

Site Status

Sentara Norfolk General Hospital

Norfolk, Virginia, United States

Site Status

Swedish Medical Center - Heart & Vascular

Seattle, Washington, United States

Site Status

University of Washington Medical Center

Seattle, Washington, United States

Site Status

University of Wisconsin Hospital

Madison, Wisconsin, United States

Site Status

Aurora Medical Group

Milwaukee, Wisconsin, United States

Site Status

Foothills Medical Centre

Calgary, Alberta, Canada

Site Status

Vancouver General Hospital

Vancouver, British Columbia, Canada

Site Status

Toronto General Hospital

Toronto, Ontario, Canada

Site Status

Institut de Cardiologie de Montreal (Montreal Heart Inst.)

Montreal, Quebec, Canada

Site Status

TUM Klinikum - Deutsches Herzzentrum München

München, Bavaria, Germany

Site Status

Deutsches Herzzentrum Berlin

Berlin, State of Berlin, Germany

Site Status

Centro Cardiologico Monzino

Milan, Lombard, Italy

Site Status

Santa Maria Hospital

Lisbon, Lisbon District, Portugal

Site Status

Kantonsspital St.Gallen

Sankt Gallen, Stgalln, Switzerland

Site Status

St. Thomas Hospital

London, London, United Kingdom

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States Canada Germany Italy Portugal Switzerland United Kingdom

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

SJM-CIP-10187

Identifier Type: -

Identifier Source: org_study_id